Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | CCR2 | P41597 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501640 | 0.91 | MAPT (0.53) | PTGDR2MAPTMAPK1CCR1CCR2 | |
| SCHEMBL4509606 | 0.86 | MAPT (0.50) | PTGDR2MAPTMAPK1SLC6A4L3MBTL1 | |
| SCHEMBL4492986 | 0.81 | PTGDR2 (0.74) | PTGDR2CCR1CCR2 | |
| SCHEMBL4512565 | 0.79 | PTGDR2 (0.48) | PTGDR2CCR1CCR2PTGDR | |
| SCHEMBL5955319 | 0.79 | CYP2C9 (0.61) | PTGDR2TDP1L3MBTL1 | |
| SCHEMBL4497285 | 0.79 | PTGDR2 (0.78) | PTGDR2PTGDR | |
| SCHEMBL4498091 | 0.75 | KDM4E (0.65) | MAPTMAPK1L3MBTL1 | |
| SCHEMBL4505489 | 0.75 | PTGDR2 (0.68) | PTGDR2CCR1CCR2TDP1PTGDR | |
| SCHEMBL4519391 | 0.74 | PTGDR2 (0.81) | PTGDR2PTGDR | |
| SCHEMBL14631662 | 0.73 | FFAR1 (0.45) | PTGDR2MAPTMAPK1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585511-B1 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1585511-A4 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1585511-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | Tularik, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | AMGEN INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004058164-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | PTGDR2 200/4885MAPT 1718/4885MAPK1 1615/4885 |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | PTGDR2 200/4885MAPT 1718/4885MAPK1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.